Corcept Therapeutics Receives US FDA Approval for Ovarian Cancer Drug
The US Food and Drug Administration (FDA) has approved Corcept Therapeutics’ relacorilant for the treatment of platinum-resistant epithelial ovarian cancer. […]
NAB-PACLITAXEL
The US Food and Drug Administration (FDA) has approved Corcept Therapeutics’ relacorilant for the treatment of platinum-resistant epithelial ovarian cancer. […]
